Why the study?
Does concomitant statin therapy reduce the antiplatelet efficacy of clopidogrel in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Does concomitant statin therapy reduce the antiplatelet efficacy of clopidogrel in patients with acute coronary syndromes or undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Despite pharmacodynamic concerns regarding a potential drug-drug interaction between clopidogrel and CYP3A4-metabolized statins, current evidence suggests this interaction does not translate into worse clinical cardiovascular outcomes.
Introduction: The use of clopidogrel is associated with a large variability in the response to this drug, wherein the results of the numerous studies indicate that even one out of three patients can be placed in the category of non responder. Corresponding section headings: Among the many causes of modified pharmacodynamic effects of clopidogrel, special attention is addressed to the possible clopidogrel-statin interaction. Numerous studies have focused on this problem, but it still seems to be missing the right answer. Conclusion: This paper reviews some of the most important facts regarding concomitant use of clopidogrel and statins, and specific issues to be addressed for safe treatment of patients.
No takes yet. Share an insight, caveat, or question.
Todorović et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: